Annamycin leukemia trial progresses toward pivotal dose selection after encouraging interim results
Moleculin Biotech's Annamycin shows 43% leukemia remission as MIRACLE data heads to ASH 2026. See what the early 2027 readout could reveal.
Pharma & Biotech
Pharma & Biotech
Moleculin reports 37% blinded remission rate as Annamycin AML trial nears critical readout
Moleculin Biotech has reported a preliminary 37% composite complete remission rate among 62 evaluable patients in Part A of its pivotal Phase 2/3 MIRACLE trial of Annamycin plus cytarabine for relapsed or refractory acute myeloid leukemia. The July 31 update also showed a 24% complete remission rate across the blinded study population. Among 30 evaluable
Pharma & Biotech
Moleculin Biotech, Inc. secures Japanese IP boost as Annamycin enters pivotal Phase 3
Moleculin secures Japanese patent for Annamycin reconstitution. Discover what this means for AML development and global market strategy.